patent.fyi
Applications  /  US 2026/0356827
United States Patent Application Publication

US 2026/0356827 A1

Published
Nov 12, 2026
Filed
Jun 24, 2026
Earliest date on the face
Sep 29, 2017
Classification
C07D 413/14
First published here
Nov 20, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Branched chain at R1

What ifWhat if R1 uses an acyclic isopropyl group to provide hydrophobic bulk?
Claim language“a C3-C6 cycloalkyl group”

The isopropyl group attaches through its methine carbon and places two methyl groups next to the attachment point. Its branching concentrates nonpolar surface near the scaffold without closing a ring.

1.1Six-membered ring at A

What ifWhat if A uses a pyridine ring to provide an aromatic surface and a hydrogen-bond acceptor?
Claim language“A 5-membered aromatic heterocyclic ring”

A pyridin-3-yl group attaches through carbon 3 and presents a planar six-membered aromatic ring. The ring nitrogen at position 1 supplies a hydrogen-bond acceptor.

1.1Methylsulfonyl group at R3

What ifWhat if R3 uses a methylsulfonyl group to provide a polar hydrogen-bond acceptor?
Claim language“a cyano group”

The scaffold bonds directly to sulfur in the –S(=O)₂CH₃ group. The two sulfonyl oxygens accept hydrogen bonds and give the substituent a strong dipole.

1.1Amide group at R3

What ifWhat if R3 uses an N-methylcarbamoyl group to retain a carbonyl at the attachment point?
Claim language“a C1-C6 alkoxycarbonyl group”

The –C(=O)NHCH₃ group attaches through its carbonyl carbon. Its carbonyl oxygen accepts a hydrogen bond, and its N–H group donates one.

1.1Open-chain ether at R2

What ifWhat if R2 uses a 2-methoxyethyl chain to present an ether oxygen?
Claim language“a 4-7 membered saturated heterocyclic group”

The –CH₂CH₂OCH₃ chain places an ether oxygen two carbons from the scaffold. The oxygen accepts a hydrogen bond, and rotation about the chain bonds changes its orientation.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Solvent reference for analytical laboratories

An analytical laboratory uses a purified spirocyclic heterocyclic derivative as a retention time and detector response reference. The laboratory prepares a concentration series by diluting a weighed stock solution with a solvent compatible with the liquid chromatography method. It injects the series alongside solvent blanks and compares retention times and peak areas across runs.

Component substitution

Sulfonamide substitution at the ring

A benzene ring occupies position A and carries a methanesulfonamido group at R3 in place of an amino group. The R3′ position carries hydrogen. Methanesulfonyl chloride reacts with the corresponding ring-bound primary amine in the presence of a tertiary amine base to form the nitrogen–sulfur bond.

Parameter or scale variation

Four point alkyl chain series

A matched series fixes R1 as methyl, A as benzene, and both R3 and R3′ as hydrogen. R2 takes four linear alkyl forms containing 1, 2, 4, or 6 carbon atoms. A shake-flask assay equilibrates each derivative in the same aqueous buffer at 25 °C for 24 hours and quantifies the dissolved fraction by liquid chromatography.

Microscale screening of crystalline salts

A 24-well plate holds 12 duplicate conditions for a derivative with a protonatable tertiary amine. The conditions combine hydrochloric, fumaric, or citric acid with two solvent compositions and acid-to-amine molar ratios of 0.5 or 1.0. Each well receives 2 mg of the derivative, and controlled evaporation yields residues for powder X-ray diffraction. Proton nuclear magnetic resonance spectroscopy or ion chromatography measures counterion content in samples with distinct diffraction patterns.

Combination with existing systems

Solid dispersion in a capsule

A capsule contains a spray-dried dispersion of a selected derivative in polyvinylpyrrolidone. The derivative and polymer dissolve in a common volatile solvent, and a spray dryer removes the solvent from atomized droplets. The dried powder is blended with microcrystalline cellulose and filled into capsules, and the polymer disperses as the capsule contents hydrate.

Automated or data-driven variant

Software guided derivative selection

A structure enumeration program attaches selected R1, R2, A, R3, and R3′ fragments to a digital template at labeled attachment points. The program checks atomic valence, preserves specified stereochemistry, and removes duplicate structures using canonical representations. It ranks the resulting structures using measured solubility and permeability from related derivatives as training data. The output records each candidate structure, its predicted properties, and the model uncertainty.

Specific version of a part

Fluorinated cyclobutyl at R1

R1 is a 3,3-difluorocyclobutyl group that attaches through carbon 1 of the four-membered ring. Both fluorine atoms occupy carbon 3.

Oxazole ring at A

A is a five-membered aromatic oxazole ring with oxygen at position 1 and nitrogen at position 3. The ring attaches to the scaffold through carbon 4.

Fluorophenoxy substituent on a ring

R3 is a 4-(4-fluorophenoxy)piperidin-1-yl group, with the piperidine nitrogen bonded to A. The phenoxy oxygen links carbon 4 of piperidine to a phenyl ring that carries fluorine para to the oxygen.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 8,071,587 B2
Published
Dec 6, 2011
Filed
May 25, 2010
Class
C07D 471/04
Document BUS 2016/0324833 A1
Published
Nov 10, 2016
Filed
Dec 19, 2014
Class
A61K 31/435
Claim 1
Document A
Document B
1.1A compound of a general formula (1) or a pharmacologically acceptable salt thereof. [The symbols in the formula are defined as follows. R1: A C1-C6 alkyl group optionally substituted with the same or different one to two substituents selected from a substituent group X, a C3-C6 cycloalkyl group optionally substituted with the same or different one to two substituents selected from the substituent group X, or a 4-7 membered saturated heterocyclic group optionally substituted with the same or different one to two substituents selected from the substituent group X R2: A C1-C6 alkyl group optionally substituted with the same or different one to two substituents selected from the substituent group X, a C3-C6 cycloalkyl group optionally substituted with the same or different one to two substituents selected from the substituent group X, or a 4-7 membered saturated heterocyclic group optionally substituted with the same or different one to two substituents selected from the substituent group X A: A 5-membered aromatic heterocyclic ring, a 6-membered aromatic heterocyclic ring, an 8-10 membered condensed aromatic heterocyclic ring, a 5-7 membered unsaturated heterocyclic ring, a 4-7 membered saturated heterocyclic ring, a benzene ring, —CH═, or a cyano group (when A is a cyano group, R3 and R3′ do not exist.) R3, R3′: R3 and R3′ are each independently a hydrogen atom, a halogen atom, a cyano group, a hydroxy group, or an oxo group, a C1-C6 alkyl group optionally substituted with the same or different one to two substituents selected from the substituent group X, a C1-C6 alkoxy group optionally substituted with the same or different one to two substituents selected from the substituent group X, a C2-C6 alkenyl group optionally substituted with the same or different one to two substituents selected from the substituent group X, a C2-C6 alkynyl group optionally substituted with the same or different one to two substituents selected from the substituent group X, a C3-C6 cycloalkyl group optionally substituted with the same or different one to two substituents selected from the substituent group X, an amino group optionally substituted with the same or different one to two substituents selected from the substituent group X, a C1-C6 alkoxycarbonyl group optionally substituted with the same or different one to two substituents selected from the substituent group X, a carbamoyl group optionally substituted with the same or different one to two substituents selected from the substituent group X, a phenyl group optionally substituted with the same or different one to two substituents selected from the substituent group X, a 5-membered aromatic heterocyclic group optionally substituted with the same or different one to two substituents selected from the substituent group X, a 6-membered aromatic heterocyclic group optionally substituted with the same or different one to two substituents selected from the substituent group X, a 5-7 membered unsaturated heterocyclic group optionally substituted with the same or different one to two substituents selected from the substituent group X, a 4-7 membered saturated heterocyclic group optionally substituted with the same or different one to two substituents selected from the substituent group X, an 8-10 membered condensed aromatic heterocyclic group optionally substituted with the same or different one to two substituents selected from the substituent group X, or R3 and R3′ may form a 5-7 membered unsaturated heterocyclic ring, a 4-7 membered saturated heterocyclic ring, or a C3-C6 cycloalkyl ring as a ring that binds to each other and condenses with A, and the ring is optionally substituted with the same or different one to two substituents selected from the substituent group X. Substituent group X: A halogen atom, a cyano group, a hydroxy group, an oxo group, a C1-C6 alkyl group, a hydroxy C1-C6 alkyl group, a C1-C6 alkoxy C1-C6 alkyl group, a C1-C6 haloalkyl group, a C3-C6 cycloalkyl group, a C3-C6 halocycloalkyl group, a phenyl group optionally substituted with the same or different one to two substituents selected from a substituent group Y, a 5-membered aromatic heterocyclic group optionally substituted with the same or different one to two substituents selected from the substituent group Y, a 6-membered aromatic heterocyclic group optionally substituted with the same or different one to two substituents selected from the substituent group Y, a 4-7 membered saturated heterocyclic group optionally substituted with the same or different one to two substituents selected from the substituent group Y, a C1-C6 alkoxy group, a C1-C6 haloalkoxy group, a C3-C6 cycloalkoxy group, a C3-C6 halocycloalkoxy group, a phenoxy group optionally substituted with the same or different one to two substituents selected from the substituent group Y, a 5-membered aromatic heterocyclic oxy group optionally substituted with the same or different one to two substituents selected from the substituent group Y, a 6-membered aromatic heterocyclic oxy group optionally substituted with the same or different one to two substituents selected from the substituent group Y, a 4-7 membered saturated heterocyclic oxy group optionally substituted with the same or different one to two substituents selected from the substituent group Y, a C1-C6 alkoxycarbonyl group, a C3-C6 cycloalkoxycarbonyl group, a carboxy group, a C1-C6 alkylcarbonyl group, a C3-C6 cycloalkylcarbonyl group, a phenylcarbonyl group optionally substituted with the same or different one to two substituents selected from the substituent group Y, a carbamoyl group, a mono (C1-C6 alkyl) aminocarbonyl group, a di (C1-C6 alkyl) aminocarbonyl group, a mono (C1-C6 alkyl) aminosulfonyl group, a di (C1-C6 alkyl) aminosulfonyl group, an amino group, a mono (C1-C6 alkyl) amino group, a di (C1-C6 alkyl) amino group, a C1-C6 alkoxycarbonylamino group, a mono (C1-C6 alkyl) aminocarbonylamino group, a di (C1-C6 alkyl) aminocarbonylamino group, a C1-C6 alkylcarbonylamino group, a phenylcarbonylamino group optionally substituted with the same or different one to two substituents selected from the substituent group Y, a 5-membered aromatic heterocyclic carbonylamino group optionally substituted with the same or different one to two substituents selected from the substituent group Y, a 6-membered aromatic heterocyclic carbonylamino group optionally substituted with the same or different one to two substituents selected from the substituent group Y, or a C1-C6 alkylsulfonylamino group Substituent group Y: A C1-C6 alkyl group, a C1-C6 alkoxy group, a halogen atom, or a hydroxy group However, as the compound of the general formula (1) or the pharmaceutically acceptable salt thereof, a compound or a pharmaceutically acceptable salt thereof of the following general formula (Z) is excluded. It should be noted that the symbols in the formula for the compound of a general formula (Z) are defined as follows. R1: A C1-C6 alkyl group or a hydroxy C1-C6 alkyl group R2: A C1-C6 alkyl group A: A 5-membered aromatic heterocyclic ring R3: A C1-C6 alkyl group, a hydroxy C1-C6 alkyl group, or a C1-C6 alkoxy C1-C6 alkyl group].
A compound according to formula I: or a pharmaceutically acceptable salt thereof wherein the C5-C6 bond can either be saturated or unsaturated; R1 is phenyl or (2-5C)heteroaryl, both optionally substituted with one or more substituents selected from R13 or R1 is (1-6C)alkyl, halogen, cyano, (2-6C)alkenyl, (2-6C)alkynyl, (3-6C)cycloalkyl, (5-6C)cycloalkenyl, (2-5C)heterocycloalkyl or (2-5C)-heterocycloalkenyl;
A · US 8,071,587 B2 · claim 1
A compound of the formula I: or a pharmaceutically acceptable salt thereof, wherein: X is R is H, or C1-6alkyl, wherein alkyl substituents are further optionally substituted with 1-4 halogen substituents, R′ is H, or C1-6alkyl, wherein alkyl substituents are further optionally substituted with 1-4 halogen substituents, R1 is OH, H, CH2OH, or C1-6alkylOC1-6alkyl, wherein alkyl substituents are further optionally substituted with 1-4 halogen substituents, or X and R1 together f
B · US 2016/0324833 A1 · claim 1

An empty cell means only that no passage was reproduced there.

Statements in these documents
Low molecular weight FSHR agonists can be used for the same clinical purposes as native FSH, i.e. for the treatment of infertility and for controlled ovarian stimulation preceeding in vitro fertilisation.
A · US 8,071,587 B2 · ¶ 5
There clearly is a need for low molecular weight hormone mimetics that selectively activate the FSH receptor.
A · US 8,071,587 B2 · ¶ 8
Selective inhibitors of the ROMK channel (also referred to herein as inhibitors of ROMK or ROMK inhibitors) are expected to represent novel diuretics for the treatment of hypertension and other conditions where treatment with a diuretic would be beneficial with potentially reduced liabilities (i.e., hypo- or hyperkalemia, new onset of diabetes, dyslipidemia) over the currently used clinical agents (see Lifton, R.
B · US 2016/0324833 A1 · ¶ 2
The continued discovery of selective small molecule inhibitors of ROMK is needed for the development of new treatments for hypertension, heart failure, edematous states and related disorders.
B · US 2016/0324833 A1 · ¶ 4
Cite aspatent.fyi, US 2026/0356827 A1, claim 1, first published 2026-11-20T07:31:16-05:00, https://patent.fyi/US20260356827/, SHA-256 be1d52238b21a132b6162db9059ba2e519c7594770b863f2c89615f02b07ce79
First published
Permanent addresshttps://patent.fyi/US20260356827/
Content fingerprint (SHA-256)be1d52238b21a132b6162db9059ba2e519c7594770b863f2c89615f02b07ce79
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi